Long COVID describes persistent multisystem symptoms (fatigue, dyspnoea, cognitive impairment, autonomic dysfunction) extending ≥12 weeks after acute SARS-CoV-2 infection.
Long COVID describes persistent multisystem symptoms (fatigue, dyspnoea, cognitive impairment, autonomic dysfunction) extending ≥12 weeks after acute SARS-CoV-2 infection. Proposed mechanisms include persistent viral fragments in reservoir tissues, endothelial activation with microclot formation, dysregulated immune memory (skewed Th1/Th17 responses, reduced regulatory T cells), and mitochondrial dysfunction. Placental mesenchymal stem cells and exosomes address these pathways through endothelial repair, anti-inflammatory cytokine secretion, and metabolic rescue of dysfunctional immune cells. Eleven registered clinical trials and two actively recruiting protocols evaluate MSC and exosome infusions in long-COVID cohorts, predominantly focusing on severe functional impairment or cardiopulmonary involvement.
| Cost indicativ · Bulgaria (UE) | €3,000–€8,000 |
|---|---|
| Gama costurilor pieței globale | €2,700–€23,000 (placidway.com) |
| Principalele tipuri de celule studiate | MSCs from Amniotic Membrane, Exosomes |
| Statutul aprobării | Investigațional |
| Studii înregistrate (ClinicalTrials.gov) | 11 · 2 recruiting now |
For the clinic's own description, see our partner clinic Stem Plus.
Published phase I safety data and small phase II trials (n=20–80 per arm) document symptomatic improvement in fatigue severity, exercise tolerance, and cognitive clarity in 40–55% of infused participants over 8–12 weeks. Objective markers—circulating microclot burden, endothelial dysfunction indices, IL-6 levels—show modest reduction in responder subgroups. One multicentre registry reports durable functional improvement (60-metre walk distance, sustained exertion capacity) persisting at 6 months in 45% of treated cohorts. Blinded controlled efficacy trials remain pending.
Depending on assessment, a Long COVID protocol may draw on:
Long-COVID MSC protocols in Sofia range €4,500–7,000 for treatment courses comprising 2–3 intravenous infusions over 6–12 weeks, alongside immunological and cardiopulmonary baseline assessment, post-treatment follow-up imaging (chest CT, echocardiography), and exercise tolerance testing. Specialised post-COVID clinics may charge facility and monitoring fees in addition to cell-preparation costs. International travel for treatment adds significantly to overall expense.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, see the Long COVID cost-by-country breakdown, or compare the best countries for Long COVID →
Before booking, check safety & regulation, the recovery climate, dacă ai putea fi candidat, and which cell type fits Long COVID.
FAQ complet Long COVID → · Defalcare costuri Long COVID →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Sunt eu un candidat? · Ce tip de celulă? · Types of clinics & best countries · Calculator de costuri
Revizuit medical de echipa editorială a StemCellAtlas cu Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) ale clinicii partenere Stem Plus (Sofia), în funcție de orientările ISSCR, FDA și EMA. Educational information, not medical advice; figures indicative.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită